Jianmin Fang, RemeGen CEO (RemeGen)

ADC ex­perts at Seagen find a $2.6B HER2 gem in Chi­na that they think can go where En­her­tu, Kad­cy­la can't

If a record IPO wasn’t enough to put Re­meGen on the map, per­haps a deal with Seagen — sport­ing $200 mil­lion in cash — might.

At the cen­ter of the li­cens­ing pact is disi­ta­m­ab ve­dotin, an an­ti-HER2 an­ti­body-drug con­ju­gate that will slide di­rect­ly in­to Seagen’s pipeline, ex­cept in cer­tain Asian coun­tries where Chi­na-based Re­meGen will be keep­ing de­vel­op­ment and com­mer­cial­iza­tion rights.

The fel­low ADC spe­cial­ists have been fol­low­ing each oth­er for quite a while, Re­meGen CEO Jian­min Fang tells me, as his trans-Pa­cif­ic team lever­aged Seagen’s link­er tech­nol­o­gy and kept it post­ed on clin­i­cal da­ta. It just hap­pens to be the right time to pull the trig­ger.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA